Laboratoire des Lyssavirus, Department of
Virology, Institut Pasteur, Paris, France
 |
INTRODUCTION |
The etiologic agent of rabies
encephalitis was believed to be unique until 1956, when the first
rabies-related viruses were isolated in Africa and Europe (for reviews,
see references 1, 26, and 43). To account for this
increasing diversity, the cross-reactivity of internal antigens (the
ribonucleoprotein complex) was used to identify the
Lyssavirus genus within the Rhabdoviridae family
(44). Virus-neutralizing antibodies (VNAbs), which
recognize the membrane glycoprotein (G), subdivided the
genus into three serotypes (44), and monoclonal antibody
studies further refined the classification into four serotypes
(10). Comparison of the viral nucleoprotein gene (N)
delineated six genotypes: four matched the previously described
serotypes (1, Rabies virus; 2, Lagos bat virus;
3, Mokola virus; and 4, Duvenhage virus), and two
additional genotypes were created for European bat
lyssavirus (EBL) type 1 (5, EBL1) and type 2 (6, EBL2)
(6). Finally, an Australian bat lyssavirus
(ABL) responsible for human cases (23, 24) was proposed to
inaugurate a seventh new genotype, which is closely related to genotype
1 (22).
The worldwide Rabies virus (genotype 1) is found in various
domestic and wild mammals, mainly carnivores, but also in American bats
(33, 47). Rabies-related viruses have so far been isolated in limited geographic regions. Lagos Bat, Mokola, and Duvenhage viruses
have been isolated in subequatorial and southern African countries,
mostly from frugivorous megachiropterans (Eidolon and Epomophorus spp.), micromammals, and insectivorous
microchiropterans (Miniopterus and Nycteris
spp.), respectively (26). EBL1 and EBL2 are widely
distributed in Europe, from Russia to Spain, mainly in coastal regions
(43). They preferentially infect insectivorous microchiropterans of Eptesicus and Myotis spp.,
respectively (1, 5). ABL was isolated along the Australian
East Coast, mainly from frugivorous megachiropterans
(Pteropus spp.) (24), but also from
insectivorous microchiropterans (23).
Virus strains of commercially available vaccines belong to genotype 1. Their spectrum of protection against the rabies-related viruses is
variable (25, 31). Pasteur virus (PV) elicits VNAbs against genotypes 1, 4, 5, and 6 but fails to protect against genotypes
2 and 3 (3, 16, 59). Differences also exist in the
pathogenicity of virus strains; genotypes 1 and 5 are pathogenic for
mice by the peripheral route, while genotype 3 is not
(37). However, all genotypes except genotype 2 have caused
human and/or animal deaths in nature.
The rabies virus transmembrane glycoprotein is
involved in tropism and pathogenicity. It is the main protecting
antigen, inducing a complete immune response with the production of
VNAbs (30, 58). The mature glycoprotein
without its cleaved signal peptide (SP) forms a trimer
(19). It is composed of an endodomain (ENDO), which
interacts with internal proteins (9, 35, 57); a
transmembrane (TM) region, and an ectodomain (ECTO), protruding from
the viral membrane. The ectodomain carries B- and T-cell antigenic
sites (4, 28) and the regions responsible for receptor
recognition (32, 51, 54, 55) and membrane fusion
(13). Several amino acid residues important for virulence
were identified in the glycoprotein (8, 12, 38, 39,
45).
Because of these attributes, we compared the glycoprotein
sequence in representative lyssaviruses from the seven genotypes and
identified two phylogroups. We evaluated the biological significance of
this phylogenetic grouping by investigating immunological and pathological properties in lyssaviruses. This is the first global approach to studying the diversity in lyssaviruses that combines genetic, pathogenicity, and immunogenicity studies.
 |
MATERIALS AND METHODS |
Viruses.
Sixteen lyssaviruses representing the seven
genotypes (minimum of two per genotype except genotype 7) were included
in this study (Table 1). Fifteen of them
were wild isolates, and one was a vaccine strain (genotype 1). Of these
isolates, 11 were previously described (5, 6, 22, 34, 41),
and 5 were received from collaborative laboratories. Bob Swanepoel
(National Institute for Virology, Johannesburg, South Africa), Donald
Lodmell (Rocky Mountain Laboratory, Hamilton, Mont.), and Hervé
Bourhy (Pasteur Institute, Paris, France) generously provided isolates from South Africa (LagSAF1, LagSAF2, and MokSAF), Montana (USA7-BT), and the Central African Republic (LagCAR), respectively. Isolates consisted of either the original infected brain or suckling mouse brain
after limited passages.
RNA extraction to sequence analysis.
Total RNA extraction,
cDNA synthesis, PCR amplification, and sequencing were done as
described by Sacramento et al. (42) with minor
modifications. Several amplicons were sequenced automatically using the
cycling and dye terminator technology in an ABI 346 analyzer. Only
positive-stranded primers were used for cDNA synthesis from the
negative-stranded viral genome, and the consensus sequence of the G
genes was determined without subsequent cloning, eliminating the
influence of individual variabilities on the observed genetic polymorphism. For sequence determination, we used 46 oligodeoxynucleotide primers (sequences available upon request) located
between nucleotide positions 2901 (upstream matrix gene M2) and 5543 (downstream polymerase gene L) with reference to the PV genome
(52, 53). Their structure was deduced either from
conserved coding regions between lyssaviruses or from genotype-specific
noncoding regions.
Sequence analysis and phylogenetic studies were performed using various
packages: GCG version 9.1 (21), ClustalW
(50), Phylip version 3.5 (17), and PAUP
version 3.1 (49).
Pathogenicity and immunogenicity studies.
BALB/c, C3H, and
Swiss mice were purchased from the Centre d'élevage et de
Recherche (Janvier, Legenest St. Isle, France). The intracerebral
(i.c.) lethal dose 50% (LD50 i.c.) was determined by
injecting 30 µl of virus into Swiss male mice (20 g) by the i.c.
route. BALB/c and C3H female mice, 6 to 8 weeks old, were injected (100 µl) by the intramuscular (i.m.) route in the thigh with 2 × 105 (PV), 6 × 105 (EBL1FRA), 3 × 107 (MokZIM), or 3 × 105 (LagNGA)
LD50 i.c. PV, EBL1FRA, and MokZIM were used as
purified viruses, and LagNGA was used as a concentrated infected BHK-21 cell supernatant as previously described (37).
Cross-neutralization was determined as described by Bahloul et
al. (3). Briefly, mice were immunized i.m. with 50 µg of plasmid DNA encoding the glycoprotein of either PV rabies
virus or Mokola virus. The capacity of mouse sera to neutralize
different lyssaviruses was evaluated 39 days postimmunization by the
rapid fluorescent focus inhibition test (48). A VNAb titer
higher than 0.5 IU/ml reflects positive seroconversion. Average VNAb titers from three mice were compared to the percent G ectodomain amino
acid identity (% ECTO aa identity).
 |
RESULTS |
Diversity of Lyssavirus glycoproteins.
To account for the genetic variability within and between
Lyssavirus genotypes, at least two isolates per genotype
(except genotype 7) were studied. These isolates were obtained over a 40-year period. Four G gene sequences (indicated in Table 1) were
retrieved from the GenBank database. Nine new G gene sequences were determined from the G to the L mRNA transcription start
signals (
2,100 bases). The sequence covers the entire G coding
sequence (
1,575 bases), including the noncoding
region (
450
bases). Using ClustalW, the glycoprotein coding region was
easily aligned among all lyssaviruses. However, the 3' noncoding region
(
) exhibited significant alignments within but not between genotypes
(data not shown). Figure 1 shows the
nucleotide and amino acid similarity profiles resulting from alignment
of the G gene coding region of lyssaviruses of the seven genotypes.
Figure 2 shows the
alignment of the deduced amino acid sequences of 13 full-length
glycoproteins from the seven genotypes and three partial
glycoproteins from Lagos bat (LagSAF1 and LagSAF2) and
Mokola (MokSAF) viruses. Both figures clearly show that the G
ectodomain is more conserved (75% average aa identity) than the SP
(35%), the TM (50%), and ENDO (40%) regions, where the hydrophobic
and hydrophilic nature, not a specific sequence, should be conserved.
The same profile was observed when only genotype 1 isolates were
compared (unpublished results), which confirms the functional
importance of the G ectodomain for lyssaviruses. In this ectodomain,
the nucleotide conservation is globally lower than the amino acid
conservation (Fig. 1), and the ratio between synonymous and
nonsynonymous substitutions
(ds/dn) is clearly
greater than 1 (data not shown). This result suggests that positive
selection is not acting on this region.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Lyssavirus similarity profile along the G
gene coding region. Nucleotide (nuc, thin line) and amino acid (aa,
bold line) sequence similarity profiles among 13 complete
Lyssavirus glycoproteins are shown
(similarityplot program of GCG; window, 100 nucleotides or 50 aa, step
1). SP, signal peptide; TM, transmembrane domain; ENDO, endodomain.
Gray boxes indicate two major antigenic sites (II and III), the minor
antigenic site (a), and the neutralizing linear epitope VI (WB+,
Western blot positive). The discontinuous line with arrowheads
indicates the region sequenced in LagSAF1, LagSAF2, and MokSAF (Fig.
2).
|
|

View larger version (88K):
[in this window]
[in a new window]
|
FIG. 2.
Multiple alignment of Lyssavirus
glycoproteins. Alignment of complete or partial deduced
amino acid sequences of the glycoprotein from genotypes 1 (PV and USA7-BT), 2 (LagNGA, LagCAR, LagSAF1, and LagSAF2), 3 (MokSAF,
MokETH, and MokZIM), 4 (DuvSAF1 and DuvSAF2), 5 (EBL1POL and EBL1FRA),
6 (EBL2FIN and EBL2HOL), and 7 (ABL). Dashes indicate amino acids
agreeing with the consensus sequence (CONSENS). Boxes with
discontinuous lines show the hydrophobic signal peptide (SP) and
transmembrane domain (TM). ECTO, ectodomain; ENDO, endodomain. Boxes
with continuous lines outline the main antigenic sites and epitopes.
Underlined NX(S/T) motifs in the ectodomain are potential
N-glycosylation sites. Phi ( ) indicates residues involved in
pathogenicity. Gray boxes show the five most conserved blocks.
|
|
The glycoprotein of lyssaviruses consists of between 503 and 514 aa. This size heterogeneity exclusively affects the ENDO (42 to
53 aa) region, but not the SP (19 aa), the ECTO (439 aa), or the TM (22 aa) region. Size and sequence diversity of ENDO could influence the
interaction of the glycoprotein with internal viral and/or
cellular proteins (35). It is noteworthy in this context
that a small stretch in the ENDO region (positions 493 to 498) is
strongly conserved (Fig. 2).
Cysteine residues are strongly conserved, indicating constraints on the
ectodomain structure. Four conserved blocks are distinguishable within
the ectodomain and corresponded to segments 58 to 89, 104 to 139, 207 to 225, and 295 to 317 (Fig. 2). These blocks are not part of the
antigenic sites or epitopes (34 to 42, 198 to 202, 264, and 330 to 338)
(4, 28), which are among the most variable regions.
Likewise, these blocks are not within the neurotoxin-like loop domain
(175 to 203), which binds to the nicotinic acetylcholine receptor
(32). However, one block (104 to 139) is within the domain
(102 to 179) proposed to promote the fusion of the viral and the
endosomal membranes, thus releasing the RNP into the cytoplasm (13). The potential N-glycosylation site at position 319 is the only one conserved in all genotypes and is located in the most
conserved region with the vesicular stomatitis virus
glycoprotein (40). This is the only site
present in the G ectodomain of the European (EBL1 and EBL2), Australian
(ABL), and American (USA7-BT) bat lyssaviruses. Therefore, it may
constitute the minimal glycosylation site sufficient to ensure adequate
maturation and routing of the glycoprotein through the
endoplasmic reticulum and Golgi apparatus (18, 46).
Additional potential glycosylation sites have been identified at
positions 202 (genotype 3), 247 (genotype 4), 184, 202, and 334 (genotype 2), and 37 (genotype 1) (unpublished results). It is not
known whether these potential sites are used in vivo. However,
glycoproteins from rabies PV and Mokola viruses having, respectively, four (37, 157, 247, and 319) and two
(202 and 319) potential sites were glycosylated to the
same degree (personal observation), suggesting that some of these sites
are not used. The effect of glycosylation on the antigenicity has been
reported previously (11), and one might expect it to
interfere in virus-host interactions (2). For instance,
some potential glycosylation sites may be located in the major
antigenic site II (202, genotypes 2 and 3) or III (334, LagNGA
isolate). The glycoprotein palmitoylation site (C461)
(20) located at the TM-ENDO junction is conserved in all
viruses except the PV strain, which has C460.
Phylogenetic relationships between lyssaviruses.
Different
phylogeny methods (neighbor joining, maximum likelihood, and parsimony)
were tested on different regions of the G gene and produced
phylogenetic trees with similar topologies. Figure
3A shows the estimated phylogenetic tree
by comparing the ectodomain nucleotide sequences. Seven distinct
lineages with significant bootstrap values (>90%) were predicted. Six
of them matched the six genotypes already defined by the N gene
sequence comparison (6). The seventh lineage (ABL), which
branches with genotype 1, corresponds to the recently proposed seventh
genotype (22). However, comparison of the ectodomain amino
acid sequences (Fig. 3B) revealed that ABL branched with genotypes 4, 5, and 6 (low bootstrap value of 50). This suggests that genotype 7 has an intermediate phylogenetic position between genotype 1 and genotypes 4, 5, and 6.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Lyssavirus phylogeny. Estimated rooted
phylogenetic trees using nucleotide (A) or amino acid (B) sequences of
the G ectodomain. The PAUP program (parsimony) was used with the
following options: branch and bound search, bootstrap with 50%
majority rule consensus, and collapsed zero-length branches. Outline
numbers are bootstrap values of 100 replicates, testing the robustness
of their corresponding internal branches. Bold numbers are steps
occurring on each branch (branch lengths). Numbers inside squares
indicate the seven genotypes. Chandipura and Piry viruses from the
Vesiculovirus genus were used as an outgroup.
|
|
The main outcome of this phylogenetic analysis is the division of the
Lyssavirus genus into two clearly distinct phylogroups supported with the strongest bootstrap values (Fig. 3). Phylogroup I
comprised genotypes 1 and 4 to 7, and phylogroup II included genotypes
2 and 3. This grouping was also supported by the ectodomain sequence
identity (Table 2). The ectodomain amino
acid identity was at least 74% within each phylogroup and less than
64% between phylogroups. The t-test showed that pairwise
ECTO aa identities were significantly higher within than between
phylogroups (P = 0.0004, 99% confidence). Genotypes 4, 5, and 6 are more homogeneous (97 to 98.5% ECTO aa identity) than
genotypes 2 and 1, which had the highest intragenotype heterogeneities
(86 and 88.5%, respectively). Between genotypes, conservation varies
from 61 to 83.5% ECTO aa identity.
Pathogenicity and immunogenicity investigations.
Particular
residues of the ectodomain considerably influence viral
pathogenicity (Fig. 2). It was shown that the presence of an R333
(or K333) in the glycoprotein is essential for the virulence of the ERA and CVS strains of rabies virus (56).
Phylogroup I viruses possess R333, whereas phylogroup II members
have an R333D replacement (Fig. 2). Thus, we tested one representative of each of the two genotypes of phylogroup II (MokZIM and
LagNGA) to determine whether they were pathogenic to adult
BALB/c and C3H mice. PV and EBL1FRA were used as controls for
phylogroup I (Fig. 4). The four viruses
were fully pathogenic when injected by the i.c. route. However, when
105 to 107 LD50 i.c. were injected
by the i.m. route, phylogroup I viruses were pathogenic but phylogroup
II viruses were not. Thus as predicted, the natural absence of R333 has
a negative effect on the pathogenicity of lyssaviruses.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Pathogenicity of lyssaviruses by the i.m. route.
Eight BALB/c mice were injected by the i.m. route in the thigh
with 105 to 107 LD50 i.c. of PV,
EBL1FRA, LagNGA, or MokZIM. For each virus, the genotype number is
indicated in parentheses. Results are expressed as the percentage of
dead animals monitored up to 17 days postinfection.
|
|
The segregation of lyssaviruses into two phylogroups was also
consistent with a previous analysis of serological cross-neutralization in mice after DNA immunization with a plasmid carrying the PV (phylogroup I) or MokZIM (phylogroup II) G gene (3).
Another study demonstrated cross-neutralization between genotypes 1 and 7 (22). Lyssavirus genotypes appeared to be
immunologically separated in the same two phylogroups. Table
3 shows the variation in mouse serum
cross-neutralization levels against representatives of six genotypes
(estimated 39 days after i.m. injection of 50 µg of plasmid DNA
encoding the G protein) according to the percent ECTO aa identity.
Immunization with the PV G gene produced a high titer of VNAbs against
viruses from genotypes 1 (53 IU/ml, 100% ECTO aa identity) and 6 (27 IU/ml, 79%) and a significant titer against viruses from genotypes 5 (4.2 IU/ml, 77.5%) and 4 (0.6 IU/ml, 76.5%). However, there was no
cross-neutralization against viruses from genotypes 3 and 2 (0 IU/ml,
64.5%). Conversely, immunization with the MokZim G gene produced a
high titer of VNAbs against genotype 3 virus (48 IU/ml, 100%), a
significant titer against genotype 2 virus (2.5 IU/ml, 78.5%), but
very weak or no neutralization against viruses from genotypes 1, 4, 5, and 6 (
0.2 IU/ml,
64.5%). Figure 5
shows that in phylogroup I there is a very good correlation
(coefficient = 0.92) between the genetic distance from PV (% ECTO
aa identity) and the neutralizing capacity of the anti-G PV sera.
Anti-Duvenhage virus VNAb titers (0.6 IU/ml) were slightly above the
accepted limit for seroconversion (0.5 IU/ml). However, the value
increased to 8 IU/ml 160 days after immunization, whereas titers
against viruses from phylogroup II remained nonsignificant (
0.4
IU/ml) (3). Figure 5 suggests that two lyssaviruses will
cross-neutralize each other if they have more than 72% ECTO aa
identity. All these data indicate that cross-neutralization exists
within but not between Lyssavirus phylogroups.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Curve of ectodomain amino acid identity versus
cross-neutralization. We correlated the cross-neutralization (mean ± standard deviation VNAb titers at day 39 post-DNA
immunization) and the G ectodomain percent identity (% ECTO aa
identity) between PV and four phylogroup I members (PV, EBL1FRA,
EBL2HOL, and DuvSAF1) (see Table 3). No significant titers
were found against two phylogroup II members (MokZIM and LagNGA). A
linear correlation between VNAb cross-neutralization and % ECTO aa
identity was observed (dashed oblique line) with a high coefficient
(r = 0.92). The horizontal dashed line at 0.5 IU/ml
corresponds to the accepted minimal titer for seroconversion. The
vertical axis was enlarged between 0 and 0.5 for convenience.
|
|
 |
DISCUSSION |
Since the first isolation of a rabies-related virus in Africa in
1956, the number of viral variants implicated in rabies encephalitis etiology has increased considerably (1, 26, 43). This led to the creation of the Lyssavirus genus in the
Rhabdoviridae family. Serotyping and genotyping are two
methods widely used to differentiate between lyssaviruses. Serotyping
showed a limitation when EBLs were isolated (5), and
genotyping lacks biological significance. The specific objective of
this work was to combine phylogenetic analysis with the study of
biological (immunopathological) characteristics (Fig.
6). Indeed, we approached the diversity
of lyssaviruses by looking at genetic, immunogenic, and pathogenic
properties. This three-axis analysis distinguished two genetically and
immunogenetically distant phylogroups; one is worldwide and pathogenic
for mice by the i.m. route of inoculation, and the other is African and apathogenic by the i.m. route.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 6.
Schematic representation of the three-axis analysis. % ECTO aa identity is a scale of distances where the seven white
arrowheads show the positions of the seven genotypes (only their
numbers are given) from PV. Phylogrouping is represented by a
horizontal box with a directional color gradient from black to gray
(intraphylogroup comparisons, 74% ECTO aa identity) to white
(interphylogroup comparisons, 64% ECTO aa identity). The phylogroup
and genotype thresholds are shown within ranges from 64 to 74% and
83.5 to 86% ECTO aa identity, respectively. VNAb titer is represented
by a horizontal box with a directional color gradient from black (high
titer) to gray (significant titer) to white (no protection, about 74%
ECTO aa identity). For pathogenicity, the presence of R333 in the
glycoprotein of phylogroup I members (PV and genotypes 1, 4, 5, 6, and 7) is an indication of their pathogenicity for mice by the
i.m. route, whereas the R333D replacement in the
glycoprotein of phylogroup II members (genotypes 2 and 3)
concords with their apathogenicity for mice by the i.m. route.
|
|
The genetic diversity of lyssaviruses was studied on the
glycoprotein, which is crucial for the virus-host
interaction, immunogenicity, and pathogenicity. The complete nucleotide
sequence of the G gene of representative lyssaviruses was determined
(
2,100 nucleotides). Phylogenetic analysis using different methods
and different regions of the G gene gave trees with similar topologies,
indicating that evolution has acted uniformly throughout the
glycoprotein. Lyssaviruses were segregated into seven
main clusters corresponding to the seven genotypes previously noted by
comparing the N gene (6, 22). However, they can be divided
into two distinct phylogroups, predicted with the strongest bootstrap
values. This dichotomy was also supported by the genetic distance;
pairwise ECTO aa identities within phylogroups were significantly
higher (
74%) than those between phylogroups (
64%). The worldwide
phylogroup I included genotypes 1, 4, 5, 6, and 7. Phylogroup II
comprised genotypes 2 and 3, which are limited to subequatorial and
southern African countries. The available data suggested that the
genotype and phylogroup thresholds were within the ranges from 86 to
83.5% and 79 to 64% ECTO aa identity, respectively. These values may be refined in the future by studying additional isolates.
We investigated the biological significance of the phylogrouping in
relation to the pathogenicity and immunogenicity of the lyssaviruses.
When inoculated in adult mice, genotype 1 and 6 viruses (phylogroup I)
were pathogenic by both the i.c. and i.m. routes. However, genotype 2 and 3 viruses (phylogroup II) were only pathogenic by the i.c. route.
Two positively charged residues within the antigenic site III, K330 and
R333, have been shown to considerably influence viral pathogenicity
(8, 12, 45). Selected antigenic mutants of rabies virus
laboratory strains in which R333 was replaced with another residue
(except lysine) were totally apathogenic for adult mice (i.c. and i.m.
routes) (56). This was possibly due to a restriction in
the type of infected neurons and in the transmission at interneurons
(7, 27, 29). An antigenic double mutant (K330N and R333M)
was unable to penetrate either motor or sensory neurons
(8). Phylogroup II members were found in nature to carry
similar replacements. In fact, viruses from genotype 3 resemble a
single (R333D) mutant, and viruses from genotype 2 resemble a double
mutant (K330L and R333D). In a genotype 1 ectodomain background, both
types of mutants would be completely apathogenic for adult mice (i.c.
and i.m. routes). Thus, it appears that mutations in positions 330 and 333 have different pathological consequences; they are less deleterious in a phylogroup II (i.c. pathogenic) than in a genotype 1 (both i.c.
and i.m. apathogenic) ectodomain background. This modulation may be due
to the local amino acid context. It has recently been proposed that
region 319 to 340 (including both the K330 and R333 residues) is
involved in the recognition of "high-affinity" neuron-specific receptors (8). It seems that the conservation of at least
one positively charged residue is necessary and sufficient for receptor recognition and penetration into sensory and motor neurons. In summary,
although the presence of an arginine (or lysine) at position 333 is
crucial, genotype 2 and 3 viruses still remain pathogenic by the i.c.
route because they possess compensatory positively charged residues at
position 331 or 334, not present in the glycoprotein of phylogroup I viruses.
Cross-neutralization between lyssaviruses was measured after DNA
immunization of mice with the G gene of a representative of each of the
two phylogroups, PV strain (genotype 1) from phylogroup I and
Mokola virus (genotype 3) from phylogroup II. Once again, lyssaviruses were segregated into two antigenic groups, which corresponded to the two phylogroups. In addition, a very good correlation was observed between the genetic distance (% ECTO aa
identity) from PV to a Lyssavirus and the capacity of the
anti-G PV serum to neutralize this Lyssavirus. It is
generally recognized that seroconversion is obtained when the VNAb
titer is over 0.5 IU/ml; thus, the range of identity where
cross-neutralization disappears is between 74% (genotype 1 versus 4, still present) and 64.5% (genotype 1 versus 2 or 3, already absent).
Indeed, the correlation curve predicts a cross-neutralization threshold at about 72% ECTO aa identity (Fig. 5). Thirty informative positions throughout the G ectodomain have nonconservative substitutions distinguishing lyssaviruses in the two defined phylogroups. It is of
interest that six of them (20%) are located in the 26 residues (6% of
the ECTO) that form the two main conformational antigenic sites. Some
or all these six nonconservative substitutions may be implicated in the
lack of cross-neutralization between the two phylogroups. Only
site-specific mutagenesis can decipher their role in immunogenicity.
Due to their African distribution, their reduced pathogenicity in mice,
and the small number of human cases and animal epizootics reported so
far (14, 15), lyssaviruses of phylogroup II (genotypes 2 and 3) could appear to be less dangerous for public and veterinary health. However, Mokola virus repeatedly emerged in South Africa between 1995 and 1998 (36), and its reservoir is still
unknown. In addition, the great genetic diversity in phylogroup II
despite a very small number of isolates should be stressed and suggests an even greater diversity in nature. For example, four lyssaviruses of
genotype 2 isolated in neighboring countries (Nigeria and the Central
African Republic) displayed only 86% ECTO aa identity. In contrast,
about 300 lyssaviruses of genotype 1 isolated worldwide still have
88.5% identity (unpublished results) and about 50 EBLs of genotypes 5 and 6 exhibited 97 and 99% identity, respectively (1).
The greater genetic heterogeneity in phylogroup II may provide
molecular flexibility. On the one hand, it could explain why several
animals vaccinated with animal vaccines (genotype 1) were protected
from challenge with Lagos bat virus (genotype 2) (16). On
the other hand, it could favor the emergence of natural D333R or D333K
mutants with increased pathogenicity. It was shown that virulent
revertants can be easily generated in vivo from avirulent strains
following a single base change at position 333 (56). One
might predict that replacing D333 of phylogroup II viruses with K (or
R) could have a dramatic positive effect on their pathogenicity, while
they may remain uncontrolled by classic vaccines (genotype 1). Such
substitutions may even be positively selected during oral vaccination
campaigns of wild vectors with classic vaccines. These campaigns are
currently limited to Europe and North America but hopefully will be
extended to Africa in the future. DNA-mediated immunization, combining
glycoprotein segments from various genotypes, has
demonstrated its potential to protect against the whole
Lyssavirus genus (3, 25). The use of such a
wide-spectrum vaccine could prevent the emergence of escaping virulent lyssaviruses.
We thank Corinne Jallet for technical assistance. We thank
Hervé Bourhy (Centre National de Référence, Institut
Pasteur, Paris, France), Courtney Meredith (Rabies Reference Centre,
OIE Regional Collaborative Centre for Africa, Onderstepoort, South Africa), Bob Swanepoel (National Institute for Virology, Johannesburg, South Africa), and Donald Lodmell (Rocky Mountain Laboratory, Hamilton,
Mont.), who provided us with isolates of rabies or rabies-related viruses. A special thank you to A. R. Gould (Commonwealth
Scientific and Industrial Research Organization), who shared the ABL G
protein sequence before publication. The help of F. Tekaia in handling computer facilities was much appreciated. We thank C. Roth for critical
reading of the manuscript. We are grateful to two anonymous reviewers
whose constructive criticism and suggestions improved the manuscript.
H.B. was a recipient of fellowships from the Moroccan Government and
from the French-Moroccan cooperation. C.B. was a recipient of a
Tunisian Government fellowship.
| 1.
|
Amengual, B.,
J. E. Whitby,
A. King,
S. Cobo, and H. Bourhy.
1997.
Evolution of European bat lyssaviruses.
J. Gen. Virol.
78:2319-2328[Abstract].
|
| 2.
|
Atanasiu, P.,
H. Tsiang,
P. Perrin, and S. Favre.
1976.
Demonstration of sialic acid in the rabies virus. Consequences of its removal on infectious and hemagglutinating properties.
C. R. Acad. Sc. Hebd. Seances Acad. Sci. D
283:111-114.
|
| 3.
|
Bahloul, C.,
Y. Jacob,
N. Tordo, and P. Perrin.
1998.
DNA-based immunisation for exploring the enlargement of immunological cross-reactivity against the lyssaviruses.
Vaccine
16:417-425[CrossRef][Medline].
|
| 4.
|
Benmansour, A.,
H. Leblois,
P. Coulon,
C. Tuffereau,
Y. Gaudin,
A. Flamand, and F. Lafay.
1991.
Antigenicity of rabies virus glycoprotein.
J. Virol.
65:4198-4203[Abstract/Free Full Text].
|
| 5.
|
Bourhy, H.,
B. Kissi,
M. Lafon,
D. Sacramento, and N. Tordo.
1992.
Antigenic and molecular characterization of bat rabies virus in Europe.
J. Clin. Microbiol.
30:2419-2426[Abstract/Free Full Text].
|
| 6.
|
Bourhy, H.,
B. Kissi, and N. Tordo.
1993.
Molecular diversity of the Lyssavirus genus.
Virology
194:70-81[CrossRef][Medline].
|
| 7.
|
Coulon, P.,
C. Derbin,
P. Kucera,
F. Lafay,
C. Prehaud, and A. Flamand.
1989.
Invasion of the peripheral nervous systems of adult mice by the CVS strain of rabies virus and its avirulent derivate AvO1.
J. Virol.
63:3550-3554[Abstract/Free Full Text].
|
| 8.
|
Coulon, P.,
J. P. Ternaux,
A. Flamand, and C. Tuffereau.
1998.
An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro.
J. Virol.
72:273-278[Abstract/Free Full Text].
|
| 9.
|
Delagneau, J. F.,
P. Perrin, and P. Atanasiu.
1981.
Structure of rabies virus: spacial relationships of the proteins G, M1, M2 and N.
Ann. Virol. (Inst. Pasteur)
132E:473-493[CrossRef].
|
| 10.
|
Dietzschold, B.,
C. E. Rupprecht,
M. Tollis,
M. Lafon,
J. Mattei,
T. J. Wiktor, and H. Koprowski.
1988.
Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implications for epidemiology and control of rabies.
Rev. Infect. Dis.
10:S785-S798.
|
| 11.
|
Dietzschold, B.,
T. J. Wiktor,
R. MacFarlan, and A. Varrichio.
1982.
Antigenic structure of rabies virus glycoprotein: ordering and immunological characterization of the large CNBr cleavage fragments.
J. Virol.
44:595-602[Abstract/Free Full Text].
|
| 12.
|
Dietzschold, B.,
W. H. Wunner,
T. J. Wiktor,
A. D. Lopes,
M. Lafon,
C. L. Smith, and H. Koprowski.
1983.
Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus.
Proc. Natl. Acad. Sci. USA
80:70-74[Abstract/Free Full Text].
|
| 13.
|
Durrer, P.,
Y. Gaudin,
R. W. H. Ruigrok,
R. Graf, and J. Brunner.
1995.
Photolabeling identifies a putative fusion domain in the envelope glycoprotein of rabies and vesicular stomatitis virus.
J. Biol. Chem.
270:17575-17581[Abstract/Free Full Text].
|
| 14.
|
Familusi, J. B., and D. L. Moore.
1972.
Isolation of a rabies related virus from the cerebrospinal fluid of a child with `aseptic meningitis.'
Afr. J. Med. Sci.
3:93-96[Medline].
|
| 15.
|
Familusi, J. B.,
B. O. Osunkoya,
D. L. Moore,
G. E. Kemp, and A. Fabiyi.
1972.
A fatal human infection with Mokola virus.
Am. J. Trop. Med. Hyg.
21:959-963.
|
| 16.
|
Fekadu, M.,
J. H. Shaddock,
D. W. Sanderlin, and J. S. Smith.
1988.
Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses.
Vaccine
6:533-539[CrossRef][Medline].
|
| 17.
|
Felsenstein, J.
1993.
PHYLIP: phylogeny inference package, version 3.52c.
University of Washington, Seattle, Wash.
|
| 18.
|
Gaudin, Y.
1997.
Folding of rabies virus glycoprotein, epitope acquisition, and interaction with endoplasmic reticulum chaperones.
J. Virol.
71:3742-3750[Abstract].
|
| 19.
|
Gaudin, Y.,
R. W. H. Ruigrok,
C. Tuffereau,
M. Knossow, and A. Flamand.
1992.
Rabies virus glycoprotein is a trimer.
Virology
187:627-632[CrossRef][Medline].
|
| 20.
|
Gaudin, Y.,
C. Tuffereau,
A. Benmansour, and A. Flamand.
1991.
Fatty acylation of rabies virus proteins.
Virology
184:441-444[CrossRef][Medline].
|
| 21.
|
Genetics Computer Group.
1997.
Wisconsin package, version 9.1.
Genetics Computer Group, Madison, Wis.
|
| 22.
|
Gould, A. R.,
A. D. Hyatt,
R. Lunt,
J. A. Kattenbelt,
S. Hengstberger, and S. D. Blacksell.
1998.
Characterisation of a novel lyssavirus isolated from pteropid bats in Australia.
Virus Res.
54:165-187[CrossRef][Medline].
|
| 23.
|
Hanna, J. N.,
I. K. Carney,
G. A. Smith,
A. E. Tannenberg,
J. E. Deverill,
J. A. Botha,
I. L. Serafin,
B. J. Harrower,
P. F. Fitzpatrick, and J. W. Searle.
2000.
Australian bat lyssavirus infection: a second human case, with a long incubation period.
Med. J. Aust.
172:597-599[Medline].
|
| 24.
|
Hooper, P. T.,
R. A. Lunt,
A. R. Gould,
H. Samaratunga,
A. D. Hyatt,
L. J. Gleeson,
B. J. Rodwell,
C. E. Rupprecht,
J. S. Smith, and P. K. Murray.
1997.
A new lyssavirus the first endemic rabies-related virus recognized in Australia.
Bull. Inst. Pasteur
95:209-218[CrossRef].
|
| 25.
|
Jallet, C.,
Y. Jacob,
C. Bahloul,
A. Drings,
E. Desmézières,
N. Tordo, and P. Perrin.
1999.
Chimeric lyssavirus glycoproteins with increased immunological potential.
J. Virol.
73:225-233[Abstract/Free Full Text].
|
| 26.
|
King, A. A.,
C. D. Meredith, and G. R. Thompson.
1994.
The biology of Southern African lyssavirus variants, p. 267-295.
In
C. E. Rupprecht, B. Dietzschold, and H. Koprowski (ed.), Lyssaviruses. Spinger-Verlag, Berlin, Germany.
|
| 27.
|
Kucera, P.,
P. Dolivo,
P. Coulon, and A. Flamand.
1985.
Pathways of the early propagation of virulent and avirulent rabies strains from the eye to the brain.
J. Virol.
55:158-162[Abstract/Free Full Text].
|
| 28.
|
Lafay, F.,
A. Benmansour,
K. Chebli, and A. Flamand.
1996.
Immunodominant epitopes defined by a yeast-expressed library of random fragments of the rabies virus glycoprotein map outside major antigenic sites.
J. Gen. Virol.
77:339-346[Abstract/Free Full Text].
|
| 29.
|
Lafay, F.,
P. Coulon,
L. Astic,
D. Saucier,
D. Riche,
A. Holley, and A. Flamand.
1991.
Spread of the CVS strain of rabies virus and of the avirulent mutant AvO1 along the olfactory pathways of the mouse after intra-nasal inoculation.
Virology
183:320-330[CrossRef][Medline].
|
| 30.
|
Lafon, M.
1994.
Immunobiology of lyssaviruses: the basis for immunoprotection, p. 145-160.
In
C. E. Rupprecht, B. Dietzschold, and H. Koprowski (ed.), Lyssaviruses. Springer-Verlag, Berlin, Germany.
|
| 31.
|
Lafon, M.,
H. Bourhy, and P. Sureau.
1988.
Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice.
Vaccine
6:362-368[CrossRef][Medline].
|
| 32.
|
Lentz, T. L.,
P. T. Wilson,
E. Hawrot, and D. W. Speicher.
1984.
Amino acid sequence similarity between rabies virus glycoprotein and snake venom curaremimetic neurotoxins.
Science
226:847-848[Abstract/Free Full Text].
|
| 33.
|
McColl, K. A.,
N. Tordo, and A. Aguilar Setien.
2000.
Bat lyssavirus infections.
Rev. Sci. Tech. Off. Int. Epizoot.
19:177-196.
|
| 34.
|
Mebatsion, T.,
J. H. Cox, and J. W. Frost.
1992.
Isolation and characterization of 115 street rabies virus isolates from Ethiopia by using monoclonal antibodies: identification of 2 isolates as Mokola and Lagos bat viruses.
J. Infect. Dis.
166:972-977[Medline].
|
| 35.
|
Mebatsion, T.,
F. Weiland, and K. K. Conzelmann.
1999.
Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G.
J. Virol.
73:242-50[Abstract/Free Full Text].
|
| 36.
|
Nel, L.,
J. Jacobs,
J. Jaftha,
B. von Teichman, and J. Bingham.
2000.
New cases of Mokola virus infection in South Africa: A genotypic comparison of southern African virus isolates.
Virus Genes
20:103-106[CrossRef][Medline].
|
| 37.
|
Perrin, P.,
M. Tino De Franco,
C. Jallet,
F. Fouque,
S. Morgeaux,
N. Tordo, and J.-H. Colle.
1996.
The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses.
Res. Virol.
147:289-299[CrossRef][Medline].
|
| 38.
|
Préhaud, C.,
P. Coulon,
A. Diallo,
C. Martinet-Edelist, and A. Flamand.
1989.
Characterization of a new temperature-sensitive and avirulent mutant of the rabies virus.
J. Gen. Virol.
70:133-143[Abstract/Free Full Text].
|
| 39.
|
Préhaud, C.,
P. Coulon,
F. Lafay,
C. Thiers, and A. Flamand.
1988.
Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence.
J. Virol.
62:1-7[Abstract/Free Full Text].
|
| 40.
|
Rose, T. K.,
R. F. Doolittle,
A. Anilionis,
P. J. Curtis, and W. H. Wunner.
1982.
Homology between the glycoproteins of vesicular stomatitis virus and rabies virus.
J. Virol.
43:361-364[Abstract/Free Full Text].
|
| 41.
|
Sacramento, D.,
H. Badrane,
H. Bourhy, and N. Tordo.
1992.
Molecular epidemiology of rabies in France: comparison with vaccinal strains.
J. Gen. Virol.
73:1149-1158[Abstract/Free Full Text].
|
| 42.
|
Sacramento, D.,
H. Bourhy, and N. Tordo.
1991.
PCR technique as an alternative method for diagnosis and molecular epidemiology of rabies virus.
Mol. Cell. Probes
6:229-240.
|
| 43.
|
Schneider, L. G., and J. H. Cox.
1994.
Bat lyssaviruses in Europe, p. 207-218.
In
C. E. Rupprecht, B. Dietzschold, and H. Koprowski (ed.), Lyssaviruses. Spinger-Verlag, Berlin, Germany.
|
| 44.
|
Schneider, L. G.,
B. Dietzschold,
R. E. Dierks,
W. Matthaeus,
P. J. Enzmann, and K. Strohmaier.
1973.
Rabies group-specific ribonucleoprotein antigen and a test system for grouping and typing of rhabdoviruses.
J. Virol.
11:748-755[Abstract/Free Full Text].
|
| 45.
|
Seif, I.,
P. Coulon,
P. E. Rollin, and A. Flamand.
1985.
Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein.
J. Virol.
53:926-934[Abstract/Free Full Text].
|
| 46.
|
Shakin-Eshleman, S. H.,
A. T. Remaley,
J. R. Eshleman,
W. H. Wunner, and S. L. Spitalnik.
1992.
N-linked glycosylation of rabies virus glycoprotein. Individual sequons differ in their glycosylation efficiencies and influence on cell surface expression.
J. Biol. Chem.
267:10690-10698[Abstract/Free Full Text].
|
| 47.
|
Smith, J. S.,
L. A. Orciari, and P. A. Yager.
1995.
Molecular epidemiology of rabies in the United States.
Semin. Virol.
6:387-400.
|
| 48.
|
Smith, J. S.,
P. A. Yager, and G. M. Baer.
1996.
A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody, p. 181-192.
In
F.-X. Meslin, M. M. Kaplan, and H. Koprowski (ed.), Laboratory techniques in rabies 4th World Health Organization, Geneva, Switzerland.
|
| 49.
|
Swofford, D. L.
1991.
Phylogenetic analysis using parsimony.
Illinois Natural History Survey, Champaign, Ill.
|
| 50.
|
Thompson, J. D.,
D. G. Higgins, and T. J. Gibson.
1994.
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res.
22:4673-4680[Abstract/Free Full Text].
|
| 51.
|
Thoulouze, M. I.,
M. Lafage,
M. Schachner,
U. Hartmann,
H. Cremer, and M. Lafon.
1998.
The neural cell adhesion molecule is a receptor for rabies virus.
J. Virol.
72:7181-7190[Abstract/Free Full Text].
|
| 52.
|
Tordo, N.,
O. Poch,
A. Ermine,
G. Keith, and F. Rougeon.
1988.
Completion of the rabies virus genome sequence determination: highly conserved domains along the L (polymerase) proteins of unsegmented negative-strand RNA viruses.
Virology
165:565-576[CrossRef][Medline].
|
| 53.
|
Tordo, N.,
O. Poch,
A. Ermine,
G. Keith, and F. Rougeon.
1986.
Walking along the rabies genome: is the large G-L intergenic region a remnant gene?
Proc. Natl. Acad. Sci. USA
83:3914-3918[Abstract/Free Full Text].
|
| 54.
|
Tuffereau, C.,
J. Bénéjean,
D. Blondel,
B. Kieffer, and A. Flamand.
1998.
Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus.
EMBO J.
17:7250-7259[CrossRef][Medline].
|
| 55.
|
Tuffereau, C.,
J. Benejean,
A.-M. Roque Alfonso,
A. Flamand, and M. C. Fishman.
1998.
Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surfaces of lepidoptera cells.
J. Virol.
72:1085-1091[Abstract/Free Full Text].
|
| 56.
|
Tuffereau, C.,
H. Leblois,
J. Bénéjean,
P. Coulon,
F. Lafay, and A. Flamand.
1989.
Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice.
Virology
172:206-212[CrossRef][Medline].
|
| 57.
|
Whitt, M. A.,
L. Buonocore,
C. Prehaud, and J. K. Rose.
1991.
Membrane fusion activity, oligomerization, and assembly of the rabies virus glycoprotein.
Virology
185:681-688[CrossRef][Medline].
|
| 58.
|
Wiktor, T. J.,
E. Gyorgy,
H. D. Schlumberger,
F. Sokol, and H. Koprowski.
1973.
Antigenic properties of rabies virus components.
J. Immunol.
110:269-276[Abstract/Free Full Text].
|
| 59.
|
Wiktor, T. J.,
R. I. Macfarlan,
C. M. Foggin, and H. Koprowski.
1984.
Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies.
Dev. Biol. Stand.
57:199-211[Medline].
|